» Articles » PMID: 36938806

Comparative Transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) Variants and the Impact of Vaccination: National Cohort Study, England

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) rapidly replaced Delta (B.1.617.2) to become dominant in England. Our study assessed differences in transmission between Omicron and Delta using two independent data sources and methods. Omicron and Delta cases were identified through genomic sequencing, genotyping and S-gene target failure in England from 5-11 December 2021. Secondary attack rates for named contacts were calculated in household and non-household settings using contact tracing data, while household clustering was identified using national surveillance data. Logistic regression models were applied to control for factors associated with transmission for both methods. For contact tracing data, higher secondary attack rates for Omicron Delta were identified in households (15.0% 10.8%) and non-households (8.2% 3.7%). For both variants, in household settings, onward transmission was reduced from cases and named contacts who had three doses of vaccine compared to two, but this effect was less pronounced for Omicron (adjusted risk ratio, aRR 0.78 and 0.88) than Delta (aRR 0.62 and 0.68). In non-household settings, a similar reduction was observed only in contacts who had three doses two doses for both Delta (aRR 0.51) and Omicron (aRR 0.76). For national surveillance data, the risk of household clustering, was increased 3.5-fold for Omicron compared to Delta (aRR 3.54 (3.29-3.81)). Our study identified increased risk of onward transmission of Omicron, consistent with its successful global displacement of Delta. We identified a reduced effectiveness of vaccination in lowering risk of transmission, a likely contributor for the rapid propagation of Omicron.

Citing Articles

Impact of disease severity, age, sex, comorbidity, and vaccination on secondary attack rates of SARS-CoV-2: a global systematic review and meta-analysis.

Sumsuzzman D, Ye Y, Wang Z, Pandey A, Langley J, Galvani A BMC Infect Dis. 2025; 25(1):215.

PMID: 39948450 PMC: 11827239. DOI: 10.1186/s12879-025-10610-5.


Relative effectiveness of COVID-19 vaccine booster doses in people aged 65 and older-a retrospective cohort study in Türkiye.

Sezerol M, Sarisaltik A Ther Adv Vaccines Immunother. 2024; 12:25151355241285375.

PMID: 39372967 PMC: 11452850. DOI: 10.1177/25151355241285375.


Risk factors for COVID-19 transmission in England: a multilevel modelling study using routine contact tracing data.

Moore H, Turner C, Rawlinson C, Chen C, Verlander N, Anderson C Epidemiol Infect. 2024; 152:e112.

PMID: 39355865 PMC: 11450508. DOI: 10.1017/S0950268824001043.


A two-variant model of SARS-COV-2 transmission: estimating the characteristics of a newly emerging strain.

Yamana T, Rajagopal S, Hall Jr D, Moustafa A, Feder A, Ahmed A BMC Infect Dis. 2024; 24(1):938.

PMID: 39251965 PMC: 11386483. DOI: 10.1186/s12879-024-09823-x.


How effective is the BNT162b2 mRNA vaccine against SARS-CoV-2 transmission and infection? A national programme analysis in Monaco, July 2021 to September 2022.

Althaus T, Overton C, Devaux I, House T, Lapouze A, Troel A BMC Med. 2024; 22(1):227.

PMID: 38840159 PMC: 11155114. DOI: 10.1186/s12916-024-03444-6.


References
1.
Veneti L, Boas H, Kristoffersen A, Stalcrantz J, Bragstad K, Hungnes O . Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Euro Surveill. 2022; 27(4). PMC: 8796289. DOI: 10.2807/1560-7917.ES.2022.27.4.2200077. View

2.
Jalali N, Brustad H, Frigessi A, MacDonald E, Meijerink H, Feruglio S . Increased household transmission and immune escape of the SARS-CoV-2 Omicron compared to Delta variants. Nat Commun. 2022; 13(1):5706. PMC: 9520116. DOI: 10.1038/s41467-022-33233-9. View

3.
Austin P . Absolute risk reductions, relative risks, relative risk reductions, and numbers needed to treat can be obtained from a logistic regression model. J Clin Epidemiol. 2009; 63(1):2-6. DOI: 10.1016/j.jclinepi.2008.11.004. View

4.
Eggink D, Andeweg S, Vennema H, van Maarseveen N, Vermaas K, Vlaemynck B . Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022. Euro Surveill. 2022; 27(4). PMC: 8796294. DOI: 10.2807/1560-7917.ES.2022.27.4.2101196. View

5.
Tessier E, Edelstein M, Tsang C, Kirsebom F, Gower C, Campbell C . Monitoring the COVID-19 immunisation programme through a national immunisation Management system - England's experience. Int J Med Inform. 2022; 170:104974. PMC: 9780018. DOI: 10.1016/j.ijmedinf.2022.104974. View